Currently, a phase 2 clinical trial is being conducted with an antibody to eotaxin-1, called Bertilimumab, in patients with ulcerative colitis (ClinicalTrial.gov, NCT01671956). The gene discussed is CCL11; the disease is ulcerative colitis.